Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 13/20 | 0.44 |
| ▸ | F3 | P13726 | 11/20 | 0.44 |
| ▸ | F2 | P00734 | 10/20 | 0.44 |
| ▸ | F10 | P00742 | 10/20 | 0.44 |
| ▸ | F11 | P03951 | 8/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2538019 | 0.85 | F2 (0.59) | F7F3F2F10F11 | |
| Trifluoroacetic Acid SCHEMBL2538391 | 0.84 | F7 (0.46) | F7F3F2F10F11 | |
| Trifluoroacetic Acid SCHEMBL4655945 | 0.83 | F7 (0.47) | F7F3F2F10F11 | |
| SCHEMBL2536769 | 0.79 | F7 (0.64) | F7F3F2F10F11 | |
| Trifluoroacetic Acid SCHEMBL4657077 | 0.79 | F7 (0.53) | F7F3F2F10F11 | |
| Trifluoroacetic Acid SCHEMBL2539624 | 0.77 | F7 (0.54) | F7F3F2F10F11 | |
| Trifluoroacetic Acid SCHEMBL2541458 | 0.76 | F7 (0.52) | F7F3F2F10F11 | |
| Trifluoroacetic Acid SCHEMBL2539699 | 0.76 | F7 (0.50) | F7F3F2F10F11 | |
| Trifluoroacetic Acid SCHEMBL2543814 | 0.72 | F7 (0.45) | F7F3F2F10F11 | |
| Trifluoroacetic Acid SCHEMBL15643025 | 0.71 | F7 (0.54) | F7F3F2F10F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996541-B1 | 2-(ARYLOXY)ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-23 | — | — | EP | disclosed |
| US-20090131473-A1 | 2-(ARYLOXY) ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-21 | — | — | US | disclosed |
| EP-1996541-A1 | 2-(ARYLOXY)ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | Bristol-Myers Squibb Company (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007103996-A1 | 2-(ARYLOXY)ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131473-A1 | 2-(ARYLOXY) ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F7, F9, F12 | F7 1/4885F3 11/4885F2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.